Skip to main content
Premium Trial:

Request an Annual Quote

Transkaryotic Therapies Licenses Cell Genesys Protein Patents

NEW YORK, June 10-Transkaryotic Therapies has licensed a set of protein patents from Cell Genesys, the company said today.

 

The license, which is exclusive, covers some of Cell Genesys' work in gene activation.

 

Under the agreement, Transkaryotic will pay $26 million in up-front license fees, including $11 million cash and $15 million in common stock. Cell Genesys may also receive milestone payments, but not royalties.

 

Transkaryotic Therapies is a publicly held company based in Cambridge, Mass. It is developing therapeutics based on protein replacement.

 

Cell Genesys is based in Foster City, Calif.

 

For further details, see the company press release.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.